Vaxcyte's VAX-31 is in a Phase 3 pivotal OPUS-1 noninferiority trial and is expecting topline data in 4Q 2026. Learn more ...
Two nationally recognized scientists with decades of experience advising U.S. vaccine policy argue that it is a mistake to ...
The UK medicines regulator has given approval for an experimental vaccine to be tested on healthy adults.
A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small clinical trial suggests. Pancreatic cancer is one of the most lethal ...
Morning Overview on MSN
A cancer vaccine is still holding melanoma at bay five years into a trial
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab continue to show ...
Health and Me on MSN
KRAS-targeted vaccine shows promise in fighting pancreatic cancer, triggers strong immune response in early trial
A new vaccine trial conducted on humans for pancreatic cancer, one of the deadliest malignancies in the world, showed immense ...
TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...
A vaccine created using artificial intelligence that could potentially provide broader protection against multiple coronaviruses and help prepare for future outbreaks has passed its first human ...
The world’s first clinical trial of a vaccine targeting the Bundibugyo strain of Ebola has begun, marking a milestone in ...
Experimental KRAS Vaccine Generates Immune Response Against Pancreatic Cancer in People at High Risk
Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an ...
New data supports the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could ...
A new peptide-based vaccine elicited antigen-specific T cell responses in high-risk patients, demonstrating proof of concept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results